Home Cart Sign in  
Chemical Structure| 850140-72-6 Chemical Structure| 850140-72-6

Structure of Afatinib
CAS No.: 850140-72-6

Chemical Structure| 850140-72-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Afatinib (BIBW 2992) is an orally active, potent, and irreversible dual specificity inhibitor of the ErbB family (EGFR and HER2) with IC50 values of 0.5 nM, 0.4 nM, 10 nM, and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M, and HER2, respectively. Afatinib is used in research on esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC), and gastric cancer.

Synonyms: BIBW 2992

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Afatinib

CAS No. :850140-72-6
Formula : C24H25ClFN5O3
M.W : 485.94
SMILES Code : O=C(NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@@H]4COCC4)/C=C/CN(C)C
Synonyms :
BIBW 2992
MDL No. :MFCD12407405
InChI Key :ULXXDDBFHOBEHA-CWDCEQMOSA-N
Pubchem ID :10184653

Safety of Afatinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Afatinib

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • EGFR/ErbB1

    EGFR (wt), IC50:0.5 nM

    EGFR (L858R), IC50:10 nM

  • HER2/ErbB2

    HER2, IC50:14 nM

  • ErbB4

    ErbB4, IC50:1 nM

  • HER2

    HER2, IC50:14 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Cos-7 cells 10 nM two weeks To screen for cell clones carrying EGFR Exon 20 insertion mutations PMC5932243
ICC10-6 100 nM 10 days To evaluate the effect of Afatinib alone or in combination with infigratinib on the viability of ICC10-6 cells PMC9064956
ICC21 100 nM 7 days To evaluate the effect of Afatinib alone or in combination with infigratinib on the viability of ICC21 cells PMC9064956
MKN7 0.5 µM 20 min To study the effect of Afatinib on EGFR and HER2 in MKN7 cells. Results showed that Afatinib slightly reduced the phosphorylation of EGFR and HER2. PMC5891041
MKN1 0.5 µM 20 min To study the effect of Afatinib on EGFR in MKN1 cells. Results showed that Afatinib reduced the phosphorylation of EGFR. PMC5891041
NCI-N87 0.5 µM 20 min To study the effect of Afatinib on HER family RTKs in NCI-N87 cells. Results showed that Afatinib alone or in combination with trastuzumab significantly reduced the phosphorylation of EGFR and HER3. PMC5891041
HCC1937 and HDQP1 cells 1 µM 5 days To evaluate the effect of afatinib in combination with other targeted therapies, the combination of afatinib and dasatinib showed the greatest growth inhibition in HCC1937 and HDQP1 cells. PMC6987485
TNBC cell lines 0.008 to 5.0 µM 5 days To assess the single-agent antiproliferative effects of afatinib, we tested the effect of afatinib on a panel of 14 TNBC cell lines, showing varying IC50 values. PMC6987485
Human cardiac microvascular ECs 50 ng/mL 1, 3, or 6 h To study the effect of VEGF treatment on Nrg1-β1 concentration PMC6553980

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice ICC21 subcutaneous xenograft model Oral 15 mg/kg Once daily for 21 days To evaluate the anti-tumor effect of Afatinib alone or in combination with infigratinib in the ICC21 subcutaneous xenograft model PMC9064956
Mice Xenograft model Subcutaneous injection 20 mg/kg Once daily for 14 days The combination treatment significantly slowed tumor growth rate and reduced Ki67 expression, inducing DNA damage PMC6737096
CB17 SCID mice H2073-SVD and H2073-ASV xenograft models Oral 7.5 or 20 mg/kg Once daily for 14 days To evaluate the anti-tumor activity of Afatinib in xenograft models carrying EGFR Exon 20 insertion mutations, showing poor efficacy in these models PMC5932243
CB17/lcr-Prkdc SCID/Crl mice HCC1806 xenograft model Oral gavage 10 mg/kg Once daily for 5 days, followed by 2 days off To evaluate the antitumour efficacy of combining afatinib and dasatinib in the HCC1806 xenograft model, the combination treatment significantly inhibited tumour growth. PMC6987485
Mice Non-small cell lung cancer patient-derived xenograft models Oral 15 mg/kg 5 days on, 2 days off, for 4 cycles Afatinib, in combination with other drugs, completely suppressed tumor growth, showing significant anti-tumor effects. PMC8763947
Mice C57BL/6J wild-type mice Oral gavage 25 mg/kg For 2 weeks To study the effect of ErbB signaling inhibition on VEGF-B-induced cardiac hypertrophy PMC6553980

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03940976 Esophageal Squamous Cell Carci... More >>noma Less << PHASE2 UNKNOWN 2020-05-01 Peking University Cancer Hospi... More >>tal and Institute, Beijing, Beijing, 100142, China Less <<
NCT00425854 Breast Neoplasms PHASE2 COMPLETED - 1200.10.3208 Boehringer Ingelh... More >>eim Investigational Site, Brussel, Belgium|1200.10.3201 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|1200.10.3203 Boehringer Ingelheim Investigational Site, Charleroi, Belgium|1200.10.3205 Boehringer Ingelheim Investigational Site, Gent, Belgium|1200.10.3204 Boehringer Ingelheim Investigational Site, Leuven, Belgium|1200.10.3206 Boehringer Ingelheim Investigational Site, Wilrijk, Belgium|1200.10.49005 Boehringer Ingelheim Investigational Site, Berlin, Germany|1200.10.49007 Boehringer Ingelheim Investigational Site, Düsseldorf, Germany|1200.10.49008 Boehringer Ingelheim Investigational Site, Erlangen, Germany|1200.10.49010 Boehringer Ingelheim Investigational Site, Essen, Germany|1200.10.49003 Boehringer Ingelheim Investigational Site, Kiel, Germany|1200.10.49004 Boehringer Ingelheim Investigational Site, Mainz, Germany|1200.10.49001 Boehringer Ingelheim Investigational Site, München, Germany|1200.10.49006 Boehringer Ingelheim Investigational Site, Wiesbaden, Germany Less <<
NCT03083678 Chordoma PHASE2 ACTIVE_NOT_RECRUITING 2025-01-31 Istituto Nazionale dei Tumori:... More >> Fondazione IRCCS, Milan, Italy|Leiden University Medical Center, Leiden, Netherlands|University College London Hospital, London, United Kingdom Less <<
NCT03486509 Squamous Cell Carcinoma PHASE2 UNKNOWN 2020-07-01 -
NCT04640870 Non Small Cell Lung Cancer|EGF... More >>-R Positive Non-Small Cell Lung Cancer|EGFR Gene Mutation Less << COMPLETED 2025-05-20 -
NCT01746251 Non Small Cell Lung Cancer PHASE2 UNKNOWN 2025-11-21 Stanford University, Palo Alto... More >>, California, 94304, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02115, United States|Massachusetts General Hospital, Boston, Massachusetts, 02115, United States|Memorial Sloan Kettering, New York, New York, 10065, United States Less <<
NCT00875433 Neoplasms PHASE2 COMPLETED - 1200.24.4403 Boehringer Ingelh... More >>eim Investigational Site, Guildford, United Kingdom|1200.24.4402 Boehringer Ingelheim Investigational Site, London, United Kingdom|1200.24.4404 Boehringer Ingelheim Investigational Site, London, United Kingdom|1200.24.4401 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom Less <<
NCT01542437 Non-Small Cell Lung Cancer|EGF... More >>R|HER-2 Less << PHASE2 COMPLETED 2025-06-17 National Cancer Institute of M... More >>exico, Mexico city, Distrito Federal, 14080, Mexico Less <<
NCT00525148 Carcinoma, Non-Small-Cell Lung PHASE2 COMPLETED 2025-08-15 1200.22.28 Boehringer Ingelhei... More >>m Investigational Site, Bakersfield, California, United States|1200.22.32 Boehringer Ingelheim Investigational Site, Beverly Hills, California, United States|1200.22.4 Boehringer Ingelheim Investigational Site, Mission Hills, California, United States|1200.22.16 Boehringer Ingelheim Investigational Site, Orange, California, United States|1200.22.19 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States|1200.22.29 Boehringer Ingelheim Investigational Site, North Miami Beach, Florida, United States|1200.22.10 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States|1200.22.18 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States|1200.22.3 Boehringer Ingelheim Investigational Site, Bethesda, Maryland, United States|1200.22.14 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States|1200.22.24 Boehringer Ingelheim Investigational Site, Flint, Michigan, United States|1200.22.5 Boehringer Ingelheim Investigational Site, Minneapolis, Minnesota, United States|1200.22.15 Boehringer Ingelheim Investigational Site, New York, New York, United States|1200.22.26 Boehringer Ingelheim Investigational Site, New York, New York, United States|1200.22.1 Boehringer Ingelheim Investigational Site, Rochester, New York, United States|1200.22.27 Boehringer Ingelheim Investigational Site, Syracuse, New York, United States|1200.22.25 Boehringer Ingelheim Investigational Site, Valhalla, New York, United States|1200.22.6 Boehringer Ingelheim Investigational Site, Canton, Ohio, United States|1200.22.7 Boehringer Ingelheim Investigational Site, Wynnewood, Pennsylvania, United States|1200.22.22 Boehringer Ingelheim Investigational Site, Mt. Pleasant, South Carolina, United States|1200.22.31 Boehringer Ingelheim Investigational Site, Fairfax, Virginia, United States|1200.22.40 Boehringer Ingelheim Investigational Site, Renton, Washington, United States|1200.22.33 Boehringer Ingelheim Investigational Site, Seattle, Washington, United States|1200.22.88604 Taichung Veterans General Hospital, Taichung, Taiwan|1200.22.88605 China Medical University Hospital, Taichung, Taiwan|1200.22.88606 Boehringer Ingelheim Investigational Site, Tainan, Taiwan|1200.22.88607 Boehringer Ingelheim Investigational Site, Taipei City, Taiwan|1200.22.88601 National Taiwan University Hospital, Taipei, Taiwan|1200.22.88602 Veterans General Hospital, Taipei, Taiwan|1200.22.88603 Chang Gung Memorial Hosp-Linkou, Taoyuan, Taiwan Less <<
NCT02044380 Carcinoma, Non-Small-Cell Lung PHASE3 COMPLETED 2025-02-16 Boehringer Ingelheim Investiga... More >>tional Site, Barrie, Ontario, Canada|Boehringer Ingelheim Investigational Site, London, Ontario, Canada|Boehringer Ingelheim Investigational Site, Newmarket, Ontario, Canada|Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada Less <<
NCT02171728 Neoplasms PHASE1 COMPLETED - -
NCT02511847 Triple Negative Breast Cancer PHASE2 UNKNOWN 2025-07-17 National Taiwan University Hos... More >>pital, Taipei City, 110, Taiwan Less <<
NCT04201756 Lung Adenocarcinoma Stage III|... More >>EGFR Gene Mutation Less << PHASE2 COMPLETED 2022-08-30 Shanghai Pulmonary Hospital, S... More >>hang'ai, Shanghai, 200433, China Less <<
NCT02171650 Neoplasms PHASE1 COMPLETED - -
NCT04909073 Non-Small Cell Lung Cancer|Epi... More >>dermal Growth Factor Receptor Mutation Less << RECRUITING 2025-12-25 Nationa University Hospital, S... More >>ingapore, Singapore Less <<
NCT01415674 Carcinoma, Squamous Cell of He... More >>ad and Neck Less << PHASE2 COMPLETED 2025-12-21 CHU d'Angers, Angers, France|I... More >>nstitut de cancérologie de l'Ouest - Site Paul Papin, Angers, France|Centre Fran?ois Baclesse, Caen, 14000, France|Centre Léon Bérard, Lyon, 69373, France|Chu de Nantes, Nantes, France|Centre Antoine Lacassagne, Nice, 06189, France|Institut Curie, Paris, 75248, France|Institut de cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|Institut Claudius Regaud, Toulouse, 31052, France|Centre Alexis Vautrin, Vandoeuvre les Nancy, 54511, France|Institut Gustave Roussy, Villejuif, 94800, France Less <<
NCT05519917 Chordoma of Clivus PHASE2 NOT_YET_RECRUITING 2025-12-30 Huashan Hospital, Shanghai, Sh... More >>anghai, 200000, China Less <<
NCT00431067 Breast Neoplasms PHASE2 COMPLETED - 1200.11.3 Boehringer Ingelheim... More >> Investigational Site, Scottsdale, Arizona, United States|1200.11.7 Boehringer Ingelheim Investigational Site, Encinitas, California, United States|1200.11.4 Boehringer Ingelheim Investigational Site, Santa Monica, California, United States|1200.11.2 Boehringer Ingelheim Investigational Site, Tampa, Florida, United States|1200.11.1 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States|1200.11.5 Boehringer Ingelheim Investigational Site, Chapel Hill, North Carolina, United States|1200.11.4401 Boehringer Ingelheim Investigational Site, Bournemouth, United Kingdom|1200.11.4402 Boehringer Ingelheim Investigational Site, Crownhill, Plymouth, United Kingdom|1200.11.4406 Boehringer Ingelheim Investigational Site, Guildford, United Kingdom|1200.11.4405 Boehringer Ingelheim Investigational Site, London, United Kingdom|1200.11.4404 Boehringer Ingelheim Investigational Site, Poole, United Kingdom|1200.11.4403 Boehringer Ingelheim Investigational Site, Truro, United Kingdom Less <<
NCT01074177 Non-small Cell Lung Cancer|EGF... More >>R Mutations Less << COMPLETED 2025-03-17 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States Less <<
NCT02271906 Lung Cancer PHASE2 TERMINATED 2017-08-16 University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less <<
NCT02629523 Lung Neoplasms|EGFR Gene Mutat... More >>ion Less << PHASE2 COMPLETED 2020-05-11 Chonnam National University Hw... More >>asun Hospital, Hwasun, Jeonnam, 58128, Korea, Republic of Less <<
NCT02423525 Brain Cancer PHASE1 COMPLETED 2025-08-21 John Wayne Cancer Institute, S... More >>anta Monica, California, 90404, United States Less <<
NCT02506517 Solid Tumors PHASE2 COMPLETED 2023-05-04 Princess Margaret Cancer Centr... More >>e, Toronto, Ontario, M5G 2M9, Canada Less <<
NCT02183883 Non-small Cell Lung Cancer PHASE2 COMPLETED 2023-03-22 Aberdeen Royal Infirmary (NHS ... More >>Grampian), Aberdeen, United Kingdom|Heart of England NHS Foundation Trust, Birmingham, United Kingdom|Beatson West of Scotland Cancer Centre (NHS Greater Glasgow & Clyde), Glasgow, United Kingdom|Barnet and Chase Farm Hospitals (Royal Free London NHS Foundation Trust), London Borough Of Barnet, United Kingdom|University College London Hospitals NHS Foundation Trust, London, NW1 2BU, United Kingdom|Cr Uk & Ucl Ctc, London, W1T 4TJ, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom Less <<
NCT02171702 Neoplasms PHASE1 COMPLETED - -
NCT02369484 NSCLC PHASE2 COMPLETED 2017-09-15 Universit?tsklinikum K?ln, K?l... More >>n, Germany|NKI-AVL, Amsterdam, Netherlands|Vall d'Hebron University Hospital, Barcelona, Spain|CHUV, Lausanne, Switzerland|USZ, Zürich, Switzerland Less <<
NCT06648096 Fanconi Anemia|Head and Neck S... More >>quamous Cell Carcinoma Less << PHASE1|PHASE2 RECRUITING 2025-12-28 Medizinische Hochschule Hannov... More >>er, Hannover, Germany|Hospital de la Santa Creu i Sant Pau, Barcelona, Catalu?a, Spain Less <<
NCT01209650 Carcinoma, Non-Small-Cell Lung APPROVED_FOR_MARKETING - 1200.47.1 Boehringer Ingelheim... More >> Investigational Site, North Ryde, New South Wales, Australia Less <<
NCT02695290 Carcinoma, Non-Small-Cell Lung... More >>|ErbB Receptors Less << PHASE4 TERMINATED 2016-08-26 1200.208.10032 Boehringer Inge... More >>lheim Investigational Site, Fountain Valley, California, United States Less <<
NCT04533321 Squamous Cell Carcinoma PHASE2 UNKNOWN 2025-09-23 National University Hospital, ... More >>Singapore, Singapore Less <<
NCT02171663 Neoplasms PHASE1 COMPLETED - -
NCT01931306 Carcinoma, Non-Small-Cell Lung APPROVED_FOR_MARKETING - The Catholic University of Kor... More >>ea, Bucheon St.Mary's Hospital, Bucheon, 14647, Korea, Republic of|Gachon University Gil Medical Center, Incheon, 405-760, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeonnam, 519-763, Korea, Republic of|Gyeongsang National University Hospital, Jinju, 660-702, Korea, Republic of|The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, 06591, Korea, Republic of|Severance Hospital, Seoul, 120-752, Korea, Republic of|Samsung Medical Center, Seoul, 135-710, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, 156-707, Korea, Republic of Less <<
NCT02514174 Carcinoma, Non-Small-Cell Lung... More >>|ErbB Receptors Less << PHASE4 COMPLETED 2019-04-25 Mayo Clinic-Arizona, Scottsdal... More >>e, Arizona, 85250, United States|Pacific Cancer Medical Center, Inc., Anaheim, California, 92801, United States|City of Hope, Duarte, California, 91010, United States|Compassionate Care Research Group, Inc. at Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, 92708, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, 90017, United States|University of Miami, Miami, Florida, 33136, United States|Ingalls Memorial Hospital, Harvey, Illinois, 60426, United States|Baystate Health D'Amour Center for Cancer Care, Springfield, Massachusetts, 01199, United States|Montefiore Medical Center, Bronx, New York, 10467, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, 19096, United States Less <<
NCT01953913 Carcinoma, Non-Small-Cell Lung PHASE3 COMPLETED 2018-07-06 307 Hospital of PLA, Beijing, ... More >>100071, China|Beijing Cancer Hospital, Beijing, 100142, China|Chinese PLA General Hospital, Beijing, 100853, China|Jilin Province Cancer Hospital, Changchun, China|Guangdong Provincial People's Hospital, Guangzhou, 510080, China|Zhejiang Cancer Hospital, Hangzhou, 310022, China|Lin Yi Tumor Hospital, Linyi, 276002, China|Jiangsu Cancer Hospital, Nanjing, 210000, China|Shanghai Chest Hospital, Shanghai, 200030, China|Fudan University Shanghai Cancer Center, Shanghai, 200032, China|Shanghai Pulmonary Hospital, Shanghai, 200433, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China|Queen Mary Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Shatin, Hong Kong|Vikram Hospital, Bangalore, 560052, India|HCG Hospital, Bengaluru, 560027, India|P VS Hospital Pvt Ltd, Calicut, 673002, India|V S Hospital, Chennai, 600031, India|Max Super Speciality Hospital, Delhi, Delhi, 110092, India|Global Hospitals, Hyderabad, 500004, India|Basavatarakam Indo - American Cancer Hospital & Research Ins, Hyderabad, 500034, India|SEAROC Cancer Centre, Jaipur, 302004, India|B. P. Poddar Hospital & Medial Research Ltd, Kolkata,West Bengal, 700053, India|Asirvatham Multispeciality Hospital, Madurai, 625 020, India|Curie Manavata Cancer Centre, Maharashtra, 422 004, India|Shatabdi Superspeciality Hospital, Maharashtra, 422005, India|Prince Aly Khan Hospital, Mumbai, 400010, India|Ruby Hall Clinic, Pune, 411001, India|National Cancer Centre, Singapore, 169610, Singapore|E-Da Hospital, Kaohsiung, 824, Taiwan|NCKUH, Tainan, 704, Taiwan|Tri-Service General Hospital, Taipei, 11490, Taiwan|Chang-Gung Memorial Hospital, Linkou, Taoyuan County, 333, Taiwan Less <<
NCT02491099 HER2/Neu+ Uterine Serous Carci... More >>noma Less << PHASE2 RECRUITING 2025-07-25 University of Arizona Cancer C... More >>enter, Tucson, Arizona, 85724, United States|Yale New Haven Hospital, New Haven, Connecticut, 06510, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States Less <<
NCT02876081 SMALL CELL LUNG CARCINOMA PHASE2 WITHDRAWN 2025-12-18 Groupe Hospitalier Paris Saint... More >> Joseph, Paris, Ile-de-France, 75014, France Less <<
NCT04206787 Non-squamous, Non-Small Cell L... More >>ung Cancer Less << COMPLETED 2023-12-22 Peking Union Medical College H... More >>ospital, Beijing, 100730, China|West China Hospital, Chengdu, 610041, China|The First Afiliated Hospital, Sun Yet-sen University, Guangzhou, 510080, China|First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China|Hainan Cancer Hospital, Haikou, 570312, China|The First Affiliated Hospital, Zhejiang University, Hangzhou, 310003, China|China Shenyang Chest Hospital, Shenyang, 110000, China|Shenzhen People's Hospital, Shenzhen, 518020, China|The First Affiliated Hospital of Zhengzhou Unviersity, Zhengzhou, 450052, China|Zhongshan People's Hospital, Zhongshan, 528403, China Less <<
NCT02780687 Urologic Neoplasms PHASE2 COMPLETED 2019-09-02 INS Bergonié, Bordeaux, 33076,... More >> France|CTR Leon Berard, Lyon, 69373, France|INS Cancérologie du Gard, N?mes, 30029, France|HOP Saint-Louis, Paris, 75010, France|HOP Cochin, Paris, 75014, France|HOP Européen G. Pompidou, Paris, 75015, France|HOP Foch, Suresnes, 92150, France|INS Universitaire du Cancer, Toulouse, 31059, France|INS Gustave Roussy, Villejuif, 94805, France|Ospedale San Donato di Arezzo, Arezzo, 52100, Italy|A.O. San Camillo Forlanini, Roma, 00152, Italy|Hospital Germans Trias i Pujol, Badalona, 08916, Spain|Hospital del Mar, Barcelona, 08003, Spain|Hospital Santa Creu i Sant Pau, Barcelona, 08025, Spain|Hospital Clínic de Barcelona, Barcelona, 08036, Spain|Hospital Vall d'Hebron, Barcelona, 08038, Spain|Hospital Universitario de Elche, Elche, 03202, Spain|Hospital Universitari de Girona Doctor Josep Trueta, Girona, 17007, Spain|Hospital Duran i Reynals, L'Hospitalet de Llobregat, 08908, Spain|Hospital Universitario Lucus Augusti, Lugo, 27003, Spain|Hospital Ramón y Cajal, Madrid, 28034, Spain|Hospital Clínico San Carlos, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital La Paz, Madrid, 28046, Spain|CIO Clara Campal, Madrid, 28050, Spain|Hospital Son Espases, Palma de Mallorca, 07010, Spain|CS Parc Taulí, Sabadell, 08208, Spain|Hospital Virgen Macarena, Sevilla, 41009, Spain|Hospital Virgen del Rocío, Sevilla, 41013, Spain|Instituto Valenciano de Oncología, Valencia, 46009, Spain Less <<
NCT04132102 Lung Squamous Cell Carcinoma PHASE4 UNKNOWN 2021-08-31 Shanghai Chest Hospital, Shang... More >>hai, Shanghai, 200030, China Less <<
NCT02208843 Carcinoma, Non-Small-Cell Lung PHASE4 COMPLETED 2017-06-13 Clinical Research Center, Alex... More >>andria University Hospital, Alexandria, 21131, Egypt|National Cancer Institute, Cairo University, Cairo, 11796, Egypt|Kasr Al Ainy Hospital, Cairo, 12311, Egypt|Nilai Medical Centre, Nilai, 71800, Malaysia|Baguio General Hospital and Medical Center, Baguio City, 2600, Philippines|St. Luke's Medical Center, Taguig, 1634, Philippines|University Clinical Center, Gdansk, Gdansk, 80-952, Poland|Specialist Hospital, Szczecin-Zdunowo, Szczecin-Zdunowo, 70-891, Poland|Oncol Centre M Sklodowska-Curie, Dept of Lung & Chest Cancer, Warsaw, 02-781, Poland|Braila County Emergency Hospital, Medical Oncology, Braila, 810303, Romania|Institute of Oncology 'Prof. Dr. Alexandru Trestioreanu', Bucharest, 022328, Romania|Sf. Nectarie Oncology Center, Craiova, Craiova, 200347, Romania|Regional Oncology Institute of Iasi, Medical Oncology, Iasi, 700483, Romania|Institute for Oncol & Radiol of Serbia, Clinic f. Med. Onco., Belgrade, 11000, Serbia|Clinical Center of Serbia, Belgrade, 11129, Serbia|Clinical Center Kragujevac, Kragujevac, 34000, Serbia|Inst. for Pulm. Diseases of Vojvodine, Clinic f. Pulm. Oncol, Sremska Kamenica, 21204, Serbia|Wattanosoth Hospital, Bangkok, 10310, Thailand|King Chulalongkorn Memorial Hospital, Bangkok, 10330, Thailand|Rajavithi Hospital, Bangkok, 10400, Thailand|Songklanagarind Hospital, Songkhla, 90110, Thailand Less <<
NCT02047903 Carcinoma, Non-Small-Cell Lung COMPLETED 2018-12-31 Multiple Locations, Germany
NCT02171637 Neoplasms PHASE1 COMPLETED - -
NCT01679405 Metastatic Disease PHASE1 TERMINATED 2025-04-16 I. Medizinische Klinik und Pol... More >>iklinik der Universit?tsmedizin, Mainz, 55131, Germany Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.06mL

0.41mL

0.21mL

10.29mL

2.06mL

1.03mL

20.58mL

4.12mL

2.06mL

References

 

Historical Records

Categories